中新网北京1月25日电 (记者 欧阳开宇)武田药品工业株式会社25日消息称，将在中国成立新的贸易公司—武田(中国)国际贸易有限公司。

Beijing Beijing on January 25 (Reuters) (Reporter OuYangKaiYu)WuTian pharmaceutical industry corporation 25 news said,Will the new trading company established in China - WuTian(China)International trade co., LTD.

　　武田药品工业株式会社说，新公司的成立将强化武田在中国市场的业务结构，同时此举也是武田继2011年9月收购奈科明公司后，在华合并该公司的重要一步。

WuTian pharmaceutical industry corporation said,The establishment of the new company will strengthen the WuTian business structure in the Chinese market,At the same time it is also WuTian after September 2011 acquisition nye families after Ming company,In China, the company's merger is an important step.

　　武田(中国)国际贸易有限公司于2013年1月正式营业，其将作为枢纽中心，为中国市场引进武田在全球生产基地生产的药品。为完成武田在中国地区对奈科明公司的合并，原奈科明咨询(上海)有限公司(奈科明上海)的约500名员工被调派至武田(中国)国际贸易有限公司以及武田在中国地区的其他分公司。此后，武田计划于2015年3月底完成对奈科明上海的清算。

WuTian(China)International trade co., LTD. In January 2013 official business,It will as a hub,For the China market in the global production base WuTian introduced the production of drugs.To complete WuTian in China to endure department Ming company merger,The original nye department Ming consulting(Shanghai)Co., LTD.(Nye department Ming Shanghai)About 500 employees been seconded to WuTian(China)International trade co., LTD in China and WuTian other branch.Since then,WuTian plan in 2015 completed by the end of march to endure department Ming Shanghai clearing.

　　武田北亚区总裁平手晴彦说，武田致力于为中国患者提供广泛的产品组合，以满足患者的不同需求。公司的新业务结构将简化分销流程、提高工作效率，以便在庞大而关键的中国市场更好地服务患者。此外，结合近期武田上海开发中心的建立，我们将及时地将新产品引入中国市场，造福中国患者。

WuTian north Asia area President deuce fine "said,WuTian for China to patients with a wide range of product portfolio,In order to meet the different needs of patients.The company's new business structure will simplify the distribution process/Improve work efficiency,In order to large and key the Chinese market better service to the patients.In addition,According to the recent WuTian the establishment of the Shanghai development center,We will timely will be new products into the Chinese market,Benefit patients with China.

　　中国是武田的第七大市场，也是其扩大新兴市场份额的战略基石。武田于1994年进军中国市场，并打下了坚实的基础，时至今日，其已拥有市场、销售、研发和生产等部门。近期，通过对奈科明公司的合并、对武田上海研发中心的投资，武田进一步巩固了自身的商业地位，并加强了临床研发能力。(完)

China is the WuTian seventh largest market,Is the expanding emerging market share strategic cornerstone.WuTian in 1994 to enter the Chinese market,And to lay a solid foundation,today,It has the market/sales/Research and development and production departments.recent,Through the merger of the Ming nai families/To WuTian Shanghai r&d center of investment,WuTian further consolidate their business status,And to strengthen the clinical research and development ability.(finish)